Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
| ▸ | CTSV | O60911 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32680893 | 0.84 | PARP1 (0.38) | PARP1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL32681001 | 0.84 | PARP1 (0.38) | PARP1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL20329099 | 0.79 | KDM4E (0.43) | SMN1; SMN2NPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL31256583 | 0.77 | L3MBTL1 (0.48) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL17125597 | 0.77 | L3MBTL1 (0.48) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL32680802 | 0.76 | PTAFR (0.35) | HPGDSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL17125599 | 0.74 | KDM4E (0.40) | ALDH1A1KDM4E | |
| SCHEMBL22809252 | 0.74 | KDM4E (0.48) | PARP1SMN1; SMN2NPC1RAB9AEGFR | |
| SCHEMBL17125598 | 0.72 | ALDH1A1 (0.40) | NPC1RAB9ALMNAKMT2AALDH1A1 | |
| SCHEMBL32680803 | 0.72 | PARP1 (0.39) | PARP1EGFRMETCTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062607-A1 | TWO-DIMENSIONAL LATTICE CONFINED SINGLE-MOLECULE-LIKE AGGREGATES | PURDUE RESEARCH FOUNDATION (US) | 2026-03-05 | — | — | US | claimed |
| US-20260062607-A1 | TWO-DIMENSIONAL LATTICE CONFINED SINGLE-MOLECULE-LIKE AGGREGATES | PURDUE RESEARCH FOUNDATION (US) | 2026-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062607-A1 | TWO-DIMENSIONAL LATTICE CONFINED SINGLE-MOLECULE-LIKE AGGREGATES | BLM, MEF2D, SNCA | PARP1 893/4885HPGD 4663/4885SMN1; SMN2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.